Caliper extends LabChip's assay range

- Last updated on GMT

Related tags: Caliper, Cell biology, Cell culture

Caliper Life Sciences has acquired a technology developed by fellow
US-based company Amphora for cell-based screening assays that can
be used on Caliper's recently introduced drug discovery platform.

Requiring only 1,000 cells per well, the new assay eliminates the requirement for extensive cell culture facilities and enables screeners to study cells that are in short supply (e.g. blood platelets and neurons), thereby opening up an area of study that is inaccessible to standard microplate-based technologies.

Caliper's LabChip 3000 system, used for automating biochemical and cell-based assays via microfluidic chips, was launched​ in February, the first major product introduction for the company since it merged with Zymark last year.

Amphora already makes use of Caliper's microfluidics technology as a platform for developing drugs and has applied it to the development of a broad assay technology that can be applied to a number of target classes, including G protein-coupled receptors.

The new technology means that certain cell lines that were not compatible with the LabChip 3000, including HEK-293 cells, a type of kidney cell used in a broad variety of applications. Caliper​ will incorporate the technology into a new calcium-flux assay for scientists studying GPCR targets.

Under the terms of the agreement, Amphora​ will transfer to Caliper its proprietary cell culture techniques, as well as various hardware and software upgrades that the firm has implemented on Caliper's proprietary microfluidic screening system.

In exchange, Caliper will compensate Amphora through a combination of cash, Caliper products, and royalties based on future sales of cell-based assays.

Related topics: Preclinical Research

Related news

Follow us

Products

View more

Webinars